EBIT: Income before interest and taxes.
Enanta Pharmaceuticals, Inc. (ENTA) had EBIT of $-85.35M for the most recently reported fiscal year, ending 2025-09-30.
| Income Statement Financials | |
$65.32M |
|
$-81.89M |
|
-- |
|
$65.32M |
|
$150.67M |
|
$-85.35M |
|
$1.80M |
|
$-83.55M |
|
$-83.55M |
|
$-81.89M |
|
$-81.89M |
|
$-81.89M |
|
$-81.89M |
|
|
EBIT |
$-85.35M |
$-80.26M |
|
21.34M |
|
21.34M |
|
$-3.84 |
|
$-3.84 |
|
| Balance Sheet Financials | |
$204.34M |
|
$35.40M |
|
$76.40M |
|
$280.73M |
|
$48.55M |
|
-- |
|
$167.46M |
|
$216.01M |
|
$64.72M |
|
$64.72M |
|
$64.72M |
|
21.39M |
|
| Cash Flow Statement Financials | |
$-19.27M |
|
$40.35M |
|
$-26.62M |
|
$41.20M |
|
$35.66M |
|
$-5.54M |
|
$18.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-130.65% |
|
-130.65% |
|
-122.86% |
|
-127.90% |
|
-125.36% |
|
$-32.17M |
|
-- |
|
-- |
|
-- |
|
0.23 |
|
-- |
|
9.49 |
|
38.45 |
|
-126.53% |
|
-126.53% |
|
-29.17% |
|
-126.53% |
|
$3.03 |
|
$-1.51 |
|
$-0.90 |
|